Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Halozyme (HALO)

Halozyme Names Dannielle Appelhans to Board of Directors

Neutral Impact 2 of 5 leadership Written later

Halozyme Therapeutics elected Dannielle Appelhans to its Board of Directors on August 14, 2026, in the class with terms ending at the 2028 annual meeting. She was not initially assigned to any Board committee, and the filing says she will receive compensation under the standard non-employee director program.

Key points

  • Board election effective August 14, 2026; term ends at the 2028 annual meeting of stockholders
  • Not initially assigned to any Board committee
  • Compensation follows the non-employee director program (cash retainers, restricted stock and stock options)
  • Filing states no arrangements or related person transactions with the company

The filing

CompanyHalozyme (HALO)
Form8-K, current report
Filed with the SECAug 18, 2026, 4:04 PM ET
Accession number0001159036-26-000106

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:12 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 18, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.